Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Schrödinger’s Bunsen agent handles 80% of computational drug discovery workload In an interview with BiopharmaTrend on October 10, Schrödinger’s chief scientific officer Robert Abel revealed that the Bunsen agent now performs approximately 80% of the company’s computational tasks on its cluster — calculations previously carried out by human computational chemists. Schrödinger plans a full commercial launch of Bunsen by the end of 2026. For 35 years, Schrödinger has sold software to pharmaceutical companies that physically simulates molecules at the atomic level to calculate how strongly a drug binds to its target protein. In 2016, Nimbus Therapeutics — co-founded by Schrödinger — sold a molecule designed using this technology to Gilead Sciences in a deal worth up to $1.2 billion, with the computations advancing it to a real drug candidate. Schrödinger released Bunsen in early access in late July. Among its first clients is pharmaceutical giant Bristol Myers Squibb: in August, BMS agreed to develop Bunsen for molecular calculations and integrate RetroSynth, a synthesis planning tool for selected molecules. Scientists describe tasks in plain language, Bunsen generates a computation plan for approval, and upon authorization, executes the full campaign without constant human oversight. Abel stated: “We recently found that about 80% of computational tasks on our cluster are now performed by Bunsen… Bunsen is doing serious work.” Inside Bunsen, a language model selects the appropriate validated method and its execution order, while the numerical result — such as binding energy — is produced by the method itself. “Numerical results come from these rigorously validated computational methods, not from the language model,” Abel said. This design avoids the chief risk of AI agents in science: plausible but physically incorrect numbers. Two years ago, in November 2024, Schrödinger CEO Ramy Farid called AI in drug discovery “nonsense,” arguing physics outperforms neural networks. At Bunsen’s July launch, he admitted: “I was extremely skeptical, honestly, and I can’t help but be glad I was wrong. This changes everything.” Agent-based systems at Schrödinger began development in late 2023, shortly after GPT-4’s release, and for 18 months they erred on simple tasks. Abel likens the moment to MYCIN, Stanford’s 1970s expert system for infection diagnosis: in a 1979 blind evaluation, physicians found MYCIN’s antibiotic recommendations acceptable in 65% of cases — higher than staff infectious disease doctors (42.5–62.5%). Yet MYCIN never entered clinical use due to legal liability for computer-based diagnoses and cumbersome data input. Bunsen differs: validation occurs at every step, and the simulation itself flags physically inconsistent results. “MYCIN had nothing like this except waiting for patient outcomes,” Abel noted. When asked whether Bunsen’s decisions are better — not just faster — Abel replied that comparing agent-assisted versus unassisted programs would be too costly an experiment. Instead, he cites two benchmarks: method accuracy and coverage — how many compounds are prioritized that would otherwise be missed. Farid in July described Bunsen’s licensing model as payment per volume of campaigns run. Abel in October clarified that formal terms remain unannounced, but the primary bottleneck for pharma companies is computational chemist time — typically juggling three to four projects simultaneously and unable to complete all necessary modeling; Bunsen frees this time. To handle growing workload ahead of full launch, Schrödinger is deploying Bunsen on Nvidia and Google Cloud infrastructure. This setup accelerates drug discovery across any therapeutic area: the agent takes on computational routine, while humans focus on question formulation and final verification. 🔗 Read original →

Stanford finds reversible way to pause liver cell metabolism without cold or low oxygen Liver transplant storage damage cut by 75% with new TorPause solution Stanford researchers have developed a method to reversibly pause liver cell metabolism without cold temperatures or reduced oxygen, using a novel solution called TorPause. In rat liver transplant models, storing organs at room temperature for five hours with TorPause reduced structural damage from 8 to 2 on a standardized scale and significantly lowered the risk of animal death. TorPause combines GSK212, an inhibitor of both mTOR and PI3K cell growth pathways, with AP39, a mitochondrial hydrogen sulfide donor that protects cells during blood flow restoration. The solution was added to the standard University of Wisconsin organ storage fluid and tested in transplantation. Control livers remained dark and congested, while those treated with TorPause retained normal color. In 14-day observation, all control and AP39-only rats died within the first day. Among rats receiving GSK212 or the full TorPause combination, one in four survived to day 14 in each group, with complete liver recovery. Risk analysis showed GSK212 reduced mortality risk by eightfold (p = 0.04). The approach mimics natural metabolic pauses seen in embryonic diapause and hibernation, targeting cellular control rather than external conditions. Previous attempts using inhaled hydrogen sulfide in mice (2005) failed in larger mammals due to concurrent oxygen deprivation, not the gas itself. Nakauchi’s team found that blocking only mTOR reduced cell growth by one-third, but dual inhibition of mTOR and PI3K produced a synergistic effect far beyond additive. GSK212 alone maintained metabolic pause in embryos for 8.5 days at normal oxygen levels, with 78% survival, while the prior hypoxic compound INK128 proved toxic under the same conditions. Combining GSK212 with AP39 addressed both metabolic suppression and reperfusion injury. Over 100,000 people in the U.S. await organ transplants, with about 17 dying daily due to donor shortages. The current storage window is limited by cold preservation, which slows but does not prevent ischemia-reperfusion injury — damage from halted and restored blood flow. Machine perfusion improves outcomes but is costly and unavailable at most clinics. Stanford has filed a patent for TorPause. Hiromitsu Nakauchi, known for work growing human organs in animals, holds stakes in unrelated biotech firms. The findings are detailed in a preprint . 🔗 Read original →

Enterobactin — a molecule gut bacteria use to scavenge iron — acts as a signal that disrupts two enzymes in roundworm neurons and extends lifespan Filipe Cabreiro’s lab at the University of Cologne systematically knocked out nearly 4,000 genes in Escherichia coli and tracked how each change affected Caenorhabditis elegans behavior. Worms exposed to bacteria overproducing enterobactin — an iron-chelating molecule — showed increased movement, better muscle preservation with age, and longer life. The preprint was posted on bioRxiv on 8 October 2026. In 2018, another group had shown enterobactin delivers iron to worm mitochondria to support larval growth; Cabreiro’s team hypothesized the same molecule might also regulate behavior, health, and aging in adult worms. In this screen, iron metabolism genes had the strongest behavioral impact: worms on bacteria lacking the fepD gene — which returns captured iron to the bacterium — moved significantly faster than normal. Without fepD, the bacterium rewires its metabolism and produces far more enterobactin to acquire iron. Knocking out enterobactin biosynthesis genes abolished the effect; adding its precursors restored it. Enterobactin is nature’s strongest known iron chelator, binding iron with an affinity constant of 10⁵² — 27 orders of magnitude stronger than EDTA, a synthetic metal chelator. To find the mechanism, researchers identified which proteins enterobactin binds. It bound most tightly to mitochondrial glutaryl-CoA dehydrogenase (GCDH). Modeling revealed the molecule sits in the same pocket where the electron carrier FAD normally resides, destabilizing the structure of two of its electron-transfer partners. In humans, mutations in this gene cause glutaric aciduria type 1, a disorder with movement impairments. The authors directly link their worm finding to this human condition: the same mitochondrial node is vulnerable both to human mutation and to bacterial enterobactin. Disrupting electron transfer raises reactive oxygen species (ROS) levels in neurons. This surge does not act as damage but as a signal: it triggers a protective program that restores cellular protein balance and extends animal lifespan. In worms, a similar “shake-up” had previously been induced by damaging Complex I or Complex IV in the electron transport chain — each activating incompatible protective programs. Enterobactin added a third, bacterial entry point. Vitamin C, as an antioxidant, blocked both the acceleration and lifespan extension; knocking out SOD-2 amplified both effects under enterobactin, while the prooxidant paraquat reproduced them alone. NMDA receptors — expected signal transducers given their overexpression in the same human disease — were blocked, contrary to expectation, which enhanced enterobactin’s effect, indicating the signal travels via another route. The true mediator turned out to be the PDFR-1 receptor — the same one previously known to regulate worm excitation and foraging. Without PDFR-1 and its neuropeptide partner, all enterobactin effects — movement, muscle health, longevity — disappeared. Cabreiro frames the finding: enterobactin is a byproduct of bacterial iron competition that accidentally hijacks an ancient neuronal pathway in the host, seizing control of it. The authors term such molecules “neuromanipulators” — bacterial compounds that tune host behavior for bacterial survival, incidentally altering host aging rates. 🔗 Read original →

ZNF865 identified as a molecular switch that reverses disc aging and pain The protein ZNF865, previously uncharacterized in the human genome, has been identified as a key regulator between healthy and aging intervertebral disc cells. Its deletion triggers cellular aging, DNA damage, and disc degeneration, while restoration reverses these processes. This first functional characterization of ZNF865 (also known as BLST) was published on October 9 in the journal Aging Cell by the tissue engineering lab at the University of Utah, which focuses on disc repair. Knocking out the gene in healthy human disc cells induces aging and DNA damage, whereas restoring it in aged disc cells from patients with back pain reverses both. In live rats, direct injection of a ZNF865-knockout construct into the disc under X-ray guidance caused degeneration and increased pain sensitivity within 5–8 weeks. Robbie Bowles leads the biomedical engineering lab at the University of Utah. Several years ago, his team screened for disc-engineering genes using CRISPR and discovered ZNF865 — a protein with no published function — initially used simply to grow disc tissue. Unexpected gene activity measurements revealed its involvement in DNA repair and cellular aging. “In short, it regulates cellular aging — which is critically important for aging and has applications in musculoskeletal diseases,” Bowles explains. ZNF865 is a zinc finger protein, a structural motif that binds DNA to activate or repress nearby genes. In humans and mice, its levels in disc cells decline with age and degeneration — a factor implicated in approximately 40% of back pain cases, one of the leading global causes of disability. When the researchers expressed ZNF865 in kidney, fat, and disc cells, all three cell types showed modulation of the same narrow set of pathways: cell division, DNA repair, and aging. Upon ZNF865 knockout in healthy disc cells, three aging markers increased 4.7- to 6.9-fold, with DNA damage rising three weeks later. Conversely, restoring ZNF865 in aged disc cells from back pain patients reduced aging and DNA damage, decreased nine out of ten SASP (senescence-associated secretory phenotype) inflammatory proteins typically secreted by senescent cells, and increased collagen production. DNA accessibility in these cells became nearly indistinguishable from healthy cells, with differences reduced by 94%. The final step involved in vivo testing: researchers injected a ZNF865-silencing construct into rat discs under X-ray control. After 5–8 weeks, animals exhibited heightened pain sensitivity, degeneration markers, and reduced disc height in one of two discs. Most rat disc degeneration models achieve this via needle puncture or enzyme injection; here, the phenotype was driven by a single gene knockout. The authors propose ZNF865 as a potential therapeutic target for aging and DNA damage across tissues, as it functions in all human cell types, and rare inherited mutations in it disrupt joints, muscles, skin, vision, and hearing. ZNF865 is the second zinc finger protein without known function identified in the past year as a master regulator of aging; in July, the same lab found ZNF512B to repair damaged DNA and suppress the same SASP profile via chromatin remodeling. Bowles is translating the discovery into therapy: “Our methods are primarily injections — easier for patients and a way to reduce opioid use.” His lab is preparing to test the same gene in conditions like Parkinson’s, where cellular aging damages neurons. 🔗 Read original →

Immune Cell Atlas of 2,609 People Finds Blood Marker of Death Comparable to Male Sex — Driven by Lifelong Herpes Virus, Age Has Little Influence October 9 in the journal Immunity, a team from Washington University in St. Louis, King’s College London, and several other institutes published findings after combining single-cell blood data from 2,609 people across four continents — totaling 12.4 million immune cells. They discovered that killer immune cells age differently among individuals of the same chronological age. To validate their protein-based immune aging score, they tested it on 48,620 participants from the UK Biobank over 17 years of follow-up. Previous human immune aging studies had poor cross-laboratory consistency, so the team compared eight independent cohorts and retained only changes reproduced in at least five. The most reliable signal was a long-known process now measured with greater precision: the thymus — the organ behind the breastbone that produces new T lymphocytes — weakens with age, reducing the output of fresh T cells in the blood. Built on this, their “immune clocks” predict a person’s age with an error of about eight years. The second discovery is largely independent of age. Among memory killer T cells (CD8 lymphocytes that destroy infected and cancerous cells), two groups exist — one uses the enzyme granzyme K, the other granzyme B. One of the lead authors, immunologist Maxim Artemov from the same university, noted that in 2023 his lab first observed this divergence in a single cohort, and by 2024 they had learned to measure thymic T-cell output via the protein CD38. In young people, the two groups are roughly equal, and age shifts this ratio only slightly: a 1.2-fold increase from ages 18 to 64, then a decline to 0.64 by age 97 — representing a separate axis of variation unrelated to aging. The balance toward granzyme B is sharply shifted by cytomegalovirus — a lifelong, usually asymptomatic herpes virus infecting most adults. In people with chronic cardiovascular disease and lupus, the skew was stronger even without the virus. This presents a pitfall for translating mouse data to humans. In old mice, granzyme K-positive T cells represent a terminally exhausted stage, a marker of tissue inflammatory aging: transferring such cells to young mice impaired memory, while blocking the enzyme improved it in old mice. In humans, however, granzyme K is carried by intermediate-stage cells, while the terminal, most inflammatory cell carries granzyme B. The human equivalent of “bad” mouse cells is not in blood but in tissues — for example, in tumors. The cause of this discrepancy remains unclear. Directly counting these cells requires expensive single-cell sequencing, impractical for large cohorts. Therefore, the team identified plasma proteins linked to the proportion of granzyme B-positive cells and trained a simple model on them. Applying it to 48,620 UK Biobank participants, they found that among 60–70-year-olds, the risk of death from any cause in the top quarter by this measure was 43% higher than in the bottom quarter — comparable to the sex difference in the same model: men had a 66% higher risk than women. The effect replicated in younger individuals independent of sex. These same individuals also had higher rates of sepsis, type 2 diabetes, gout, liver disease, and kidney failure — but not dementia or Parkinson’s disease. The map connects immune profile to mortality risk, but no drugs or protocols currently exist to correct the granzyme balance. Five co-authors, including Artemov, have filed a preliminary patent application for the protein test itself. 🔗 Read original →

Aging Is Not Random DNA Chaos — It’s a Choice of What Cells Protect Nathaniel David, cofounder of Unity Biotechnology, compared a long-lived tortoise and dogs to propose a testable hypothesis about transposons On October 10, Nathaniel David, cofounder of Unity Biotechnology — a biotech firm developing drugs against cellular aging — posted a thread on X comparing two recent findings: gene stability in Jonathan, a 194-year-old tortoise, and loss of control over mobile DNA segments in large dog breeds. From this comparison, he derived a unified principle of aging and a testable hypothesis about the sequence of events in dogs. Comparing mice and whales is meaningless: they differ in a million ways, and it’s unclear which matters for aging. Instead, David compares nearly identical animals with sharply different lifespans within a single species — dog breeds or Jonathan and his kin, who typically don’t live past 100. Jonathan’s epigenome — the pattern of chemical marks on DNA that turn genes on and off — showed that with age, these marks scatter chaotically across the genome everywhere except at promoters of mitochondrial genes, RNA processing genes, and DNA repair genes — where they remain sharp, as in a five-year-old hatchling. Jonathan also has extra copies of DNA repair genes and ten copies of the perforin gene — versus seven in another giant tortoise, Lonesome George. Perforin lets immune cells punch holes in target cells’ membranes; extra copies may enhance the removal of senescent and cancerous cells. In dogs, the pattern is mirrored. Analysis of methylation across breeds of different sizes revealed that large breeds — which live shorter lives than small ones — lose methylation fastest on transposons: DNA segments capable of copying themselves and inserting into new genome locations, especially the youngest ones. David synthesizes both facts into a thesis: Aging is not about avoiding disorder. It’s about choosing where to allow it. The tortoise protects mitochondrial and DNA repair genes; dogs first lose control over transposons. “Everything degrades. What matters is what you protect,” he writes. Epigenetic clocks — estimates of biological age based on methylation patterns — run faster in youth for dogs, not old age: a large breed appears epigenetically older than a small breed of the same age, even though damage accumulation should accelerate clocks later in life. David interprets this as an ongoing developmental program: “Aging is more like growth that never stops than like wear and tear.” This explains an old paradox: within a species, larger individuals live shorter lives; between species, the opposite usually holds. Within a species, extra size means extra growth on a fixed tissue repair budget; between species, evolution raises the budget alongside size — along with extra DNA repair and perforin gene copies in the tortoise. According to David, for humans, each year by which epigenetic age outpaces chronological age raises mortality risk by 2%; for dogs, it’s 15%. But dogs live roughly six times shorter than humans, so when scaled to fraction of lifespan, the effect is equivalent. He calls the dog study solid and the tortoise work a hypothesis: one animal versus four, and part of the tortoise paper’s genetic analysis, in his view, doesn’t support its conclusions. Together, they yield a testable prediction: if transposon derepression drives aging — rather than merely marking it — it should precede inflammation and cancer in dogs, especially in larger breeds. He invites the authors of the same dog project to test this. 🔗 Read original →

Terrence Tao posed a thought experiment: AI found a cancer drug that passed trials without a clear mechanism — would you take it? The debate split social media, and an oncologist reminded Tao that medicine has long treated patients with drugs whose mechanisms are not fully understood. On October 9, 2026, Terrence Tao delivered a lecture titled “Math 2.0” at Caltech, featuring a slide: AI discovers a cancer drug without an understandable mechanism. The next day, a screenshot of the slide garnered over 9,000 likes and 1.2 million views on X. Oncologist Vinay Prasad responded: medicine already uses drugs with incompletely understood mechanisms of action. Tao, a Fields Medalist — the highest honor in mathematics — expanded on an idea from his July lecture: mathematics is entering an era of proof abundance, where AI generates proofs faster than humans can absorb them. Previously, seeking solutions built understanding of the field; now, chasing answers alone severs that connection. In pure mathematics, this substitution is safe: Lean verifies proofs line by line without missing errors. Tao’s thought experiment shows that even such verification fails in the real world: AI selects a cocktail of substances, Lean confirms its mathematical model, the cocktail passes final third-phase human trials — yet the question remains: did it cure cancer, or merely exploit a weakness in the trial procedure, with no one understanding its mechanism? “Could an AI solution to this request be misaligned because it exploits a flaw in the trial procedure itself? Before injecting this cocktail into your blood, would you want to know that at least one human oncologist understands its mechanism?” Tao had raised the same risk in early September using the Navier–Stokes equations, which describe fluid motion: an AI solution found by bypassing human discovery deprives the field of new ideas born from the search process itself. On the cancer slide, the same error stands not for proof, but for patient health. Reviewer Andrew Carran posted the slide photo: if the drug works, a patient with stage IV cancer doesn’t care whether anyone understands its mechanism. User kenbwork agreed: we don’t need AI dosing incomprehensible drugs. Another critic replied sharply: the mathematician “is laying rhetorical groundwork for banning AI cancer drugs” and “will kill people.” Everyone responded to Carran’s summary — no one discussed the slide’s actual phrasing about exploiting a flaw in the trial procedure. Prasad — a hematologist-oncologist, professor at UC San Francisco, who twice led the FDA’s biologics unit in 2025–2026 and twice resigned after criticism — replied to Carran’s version. Six months earlier, he had established a single pivotal trial as standard, replacing the prior requirement of two. The mechanism of many cancer drugs remains incompletely understood: no general theory for doxorubicin, no one knows why sevoflurane gas turns off consciousness. “If AI creates a cancer drug whose mechanism nobody understands, but it passes a full randomized third-phase trial, no cancer patient on Earth would say ‘no, thank you.’ Today we accept far less evidence.” Prasad is medically correct, but Tao’s question remains unanswered: did the trial confirm cure, or merely the ability to evade the testing procedure? Tao proposes not a ban, but open mathematical models for interpretability and safety, promised soon. Whether medicine deems trial statistics sufficient — or demands an explained mechanism — will determine how quickly AI drugs reach patients who have nothing left to wait for. 🔗 Read original →

Birth weight and breastfeeding influence organ aging decades later, UK Biobank study shows A study of 44,800 UK Biobank participants, published in Aging Cell on 9 October, links early-life factors to the pace of organ aging across 19 body systems. Researchers built organ-specific “aging clocks” using levels of nearly 3,000 blood proteins, then correlated them with birth weight (available for 21,400 participants) and breastfeeding history (recorded for 29,700). Higher birth weight — adjusted for lifestyle and existing disease — was associated with slower aging in 11 of the 19 systems, strongest in the gut, oesophagus, and stomach. Notable effects also appeared in the immune system, kidneys, liver, salivary glands, thyroid and adrenal glands, skin, and muscles. Breastfeeding selectively slowed aging in the gut and adrenal glands but accelerated it in the thyroid, a finding the authors call unexpected, possibly due to unstable iodine and thyroid hormone levels in milk stressing the infant’s immature gland. When both factors were present, their combined effect exceeded a simple sum: for the gut, the joint impact was nearly twice as strong as birth weight alone. The researchers identified a partial mechanism for birth weight’s effect: “allostatic load” — the cumulative wear from chronic stress, measured via metabolic, cardiovascular, and inflammatory markers — explained up to 35% of the link with accelerated skin aging and 30% for adrenal glands, but far less for the gut and stomach, suggesting a more local process there. For breastfeeding, allostatic load explained none of the observed effects, pointing instead to early influences like milk composition and gut microbiota establishment. Both effects were stronger in women and those with higher socioeconomic status, indicating that later-life experiences shape how early advantages unfold. Participants self-reported birth weight and breastfeeding in mid-to-late life. Though such recall typically weakens true associations, nine of the eleven birth weight links remained significant even after adjusting for both factors, supporting the robustness of the findings. The study builds on organ-specific aging clocks first developed in small cohorts in 2023 and scaled to UK Biobank in 2025. A Scottish validation of the same clocks, published 1 October, found them less accurate than brain MRI and three other methods for predicting mortality. 🔗 Read original →

Loss of Lamin B1 Triggers Mitochondrial Failure in Aging Bone Stem Cells, Weakening Bones — Approved Drug Nalmefene Breaks the Chain In aging bone stem cells, researchers identified a complete cascade of failures — from loss of nuclear protein Lamin B1 to mitochondrial dysfunction — that weakens bones, and found an already-approved drug that breaks this chain. Scientists from Sun Yat-sen University in Shenzhen traced the mechanism in patient cells and mice, publishing their findings on October 8. They showed that age-related loss of Lamin B1 activates the gene SLC7A11, damages actin — the cell’s structural protein — through excess sulfur bonds, and halts mitochondrial division. Among approved drugs, nalmefene — used for opioid-induced constipation — blocks this link. Bone is constantly renewed: some cells break it down, while bone marrow stem cells build new bone. In aging people, breakdown outpaces formation, leading to senile osteoporosis, but why stem cells fail to build bone was unclear. The authors began with Lamin B1, a nuclear envelope protein whose loss is considered a hallmark of cellular aging. Normally, it “tethers” DNA regions to the nuclear envelope, keeping them silenced. When Lamin B1 disappears, DNA packaging weakens, and a “super-enhancer” — a cluster of regulatory elements — forms, sharply activating one gene. Among genes in these regions, only one showed abnormal activity in both aging and osteoporosis: SLC7A11, a pump that imports the amino acid cystine into the cell. Excess SLC7A11 floods the cell with more cystine than it can process: lacking sufficient NADPH reductase, cystine forms abnormal sulfur bonds in actin — a process discovered in 2023 in cancer cells and termed disulfideptosis; the original paper has already garnered nearly a thousand citations. Cancer cells require external glucose deficiency for this; aged bone stem cells do not: they poorly uptake glucose and produce less NADPH even in nutrient-rich conditions. Collapsed actin fails to retain the protein DRP1, which divides mitochondria: without division, damaged mitochondrial fragments are not cleared, mitochondria produce less energy, and the cell lacks the strength to become a bone-forming cell. To prove causality, the authors generated mice lacking Lamin B1 specifically in bone cells — these mice developed accelerated osteoporosis. Separately, in 18-month-old mice (mouse equivalent of old age), knocking out SLC7A11 prevented bone loss, as seen in normal old mice. In the decisive experiment, mice lacking Lamin B1 also had SLC7A11 knocked out — bone loss did not occur, confirming SLC7A11 acts downstream of Lamin B1. The same chain was confirmed in bone marrow from elderly patients, and genomic analysis linked LMNB1 variants to osteoporosis risk. Since Lamin B1, as a structural protein, is difficult to target with drugs, and SLC7A11 is a membrane pump with a known 3D structure, the researchers screened it against a library of approved drugs and identified nalmefene — a Japanese pharmaceutical from Shionogi that blocks intestinal opioid receptors to treat opioid-induced constipation. A 30-day treatment restored bone mass in osteoporotic mice and accelerated skull defect healing, without altering blood, liver, kidney, or heart markers. SLC7A11 also has a protective function — in cancer cells, it shields against ferroptosis, another form of cell death, and excessive inhibition may pose this risk. Therefore, the authors call nalmefene dosing a matter of fine-tuning, and the drug’s link to SLC7A11 a conclusion drawn from docking and simulation. California biologists have linked the waning efficacy of osteoporosis drugs to therapies that accelerate overall bone turnover rather than targeting the bone stem cell pool itself; nalmefene’s target is precisely there, and its safety is already established — albeit for a different indication. 🔗 Read original →

Muscle aging and early Alzheimer’s trigger the same inflammatory program in blood vessels and immune cells — two genes identified as potential common switches A team from Zhejiang University and Amsterdam University Medical Center compared gene activity in old and young muscle with data from human brains at early Alzheimer’s stage. Inflammatory gene sets matched in blood vessels and immune cells of both tissues, and a similar signal was found in the blood of living people. A computational model pointed to two genes whose virtual “switching off” consistently dampened inflammation in both tissues. The idea that weakening muscles and a fading brain are manifestations of one process has long centered on proteins muscles release into the blood, like irisin. This preprint from October 8 — a scientific article prior to journal publication — shifts the idea to the cellular level: which genes are active in muscle and brain. On the muscle tissue atlas — nearly 300,000 cells from young and elderly donors — inflammatory gene activity rose in 11 of 15 cell types in older individuals, and intercellular signaling increased by 77%. For the brain, they used the Allen Institute atlas — 1.1 million cell nuclei from 84 donors with a continuous severity scale based on autopsy, not a binary “healthy or sick” diagnosis. On the early stage of this scale, brain immune cells and vessels showed the same rise in inflammatory programs. As disease progressed further, brain cell signaling networks weakened: total strength dropped nearly 20%, and activity in 38 of 39 inflammatory pathways — groups of genes activated together — declined, which is why early Alzheimer’s was compared to muscle aging. The authors then focused on genes in vascular and immune cells — the only cell types with comparable roles in muscle and brain. Six of eight inflammatory pathways matched in vascular cells (109 shared genes), and four of eight in immune cells (51 genes). A similar stable cross-species inflammatory cell subgroup had been found before in another tissue: in mice, baboons, and humans, a pro-inflammatory subgroup of lung alveolar macrophages increased more than tenfold with age. In blood, the signal varied in strength: with physical frailty — weakness and slow gait — the same pathways were active in 30 of 36 “pathway–cell type” checks; with mild cognitive impairment, only one; with Alzheimer’s, five. In two independent blood donor groups, 23 of 30 checks confirmed the same direction. In a computational model of gene regulatory links, the authors virtually switched off 18 candidate genes one by one, comparing effects in both tissues for 13 of them. Only ETS2 and BHLHE40 showed stable, predictable weakening of inflammatory programs across all donors, passing all model stability checks. The authors call this pair a hypothesis for lab testing: the effect did not survive statistical correction, and muscle and brain samples came from different people — so the “muscle → brain” link remains to be proven experimentally. ETS2 has another history: in June 2024, the Francis Crick Institute showed in Nature that its overactivity recreates inflammation in Crohn’s disease and ulcerative colitis, and MEK inhibitors blocking its activation suppress inflammation in cell experiments. BHLHE40 is known otherwise: in T-cells it sets the balance between inflammatory and anti-inflammatory signals, and in macrophages it governs their proliferation. This preprint translates the idea of muscle and brain aging into a list of matching genes and names molecules whose connection might be tested for disruption. 🔗 Read original →

Space Biostasis Summit Announces 30 Speakers: Cryobiologist Greg Fahy, Hibernation Researcher Sinisa Hrvatin, and Two ARPA-H Managers Focus on Controlled Metabolic Pause for Space On October 9, the nonprofit Space Biostasis Coalition announced the speaker list for its upcoming summit, confirming 30 presenters including cryobiologist Greg Fahy, hibernation researcher Sinisa Hrvatin, and two ARPA-H managers. The summit website confirms the program: the conference will take place February 9–11, 2027, at Space Center Houston, adjacent to NASA’s Johnson Space Center where astronauts are trained. The theme centers on engineering pathways to a controlled metabolic pause in humans for deep-space travel. Over six months of spaceflight, the body deteriorates predictably: according to coalition calculations, bones lose about 10% of density, muscles lose 15% of mass, the heart ages as if an extra 10 years have passed, and NASA data shows kidney stone risk increases sevenfold. A one-way trip to Mars takes seven to nine months: each crew day adds mass and cost to the spacecraft. NASA has pursued solutions since 2013, when it proposed a crew transport module with induced hibernation, and in 2024 supported the STASH experiment on the ISS — testing whether such hibernation protects animals from muscle and bone loss in microgravity. The European Space Agency calculated that crew hibernation could reduce a Mars-bound spacecraft’s size by one-third. Biostasis is an umbrella term for controlled, reversible metabolic arrest. The coalition’s website breaks it down by methodological maturity: hypothermia — routine in cardiac surgery and resuscitation — maintains pause for minutes; synthetic torpor — experimental activation of brain neurons in mice and hamsters — extends it to days; cryostasis at near-zero temperatures is designed for weeks for tissues and organs; vitrification — replacing ice with a glass-like state without cellular destruction — holds pause for millennia in theory but has only been proven for individual animal tissues, not whole organisms. For over a decade, NASA, ESA, cryobiologists, hibernation biologists, and federal grantmakers pursued this agenda separately — the summit is the first to bring them together. The speaker list includes Greg Fahy of 21st Century Medicine, developer of the M22 solution, which in the 2000s set an unmatched record: a vitrified, rewarmed, and transplanted rabbit kidney sustained the animal’s life. Also featured is Sinisa Hrvatin of the Whitehead Institute at MIT: his lab identified hypothalamic neurons triggering torpor in mice, and in a Nature Aging study, his team showed that repeatable artificial torpor slowed epigenetic aging in mouse blood by nearly 40%. ARPA-H, the U.S. Health Department’s agency for high-risk medical programs, has no dedicated space hibernation program: at the summit it is represented by two managers — Gloria Elliott leads an $87 million program for storing cellular products without deep freezing, and a parallel effort for donor organs; Jean Eber leads the FRONT program, aiming to replace aging brain tissue via transplants. One community works on both earthly organ storage and spaceflight — via whole-human metabolic pause.… 🔗 Read original →

Same neural receptor protects roundworm from Alzheimer’s and Huntington’s proteins by opposite mechanisms A single neuronal receptor in the roundworm *Caenorhabditis elegans* defends against Alzheimer’s by breaking amyloid-beta into harmless fragments, while protecting against Huntington’s by clumping the mutant huntingtin protein into large, inert aggregates, researchers from the Hebrew University of Jerusalem report in *Science Advances*, October 9, 2024. The study resolves a paradox first noted by the lab in 2013: loss of the gtr-1 receptor worsened heat sensitivity but shielded worms from amyloid-beta toxicity. Now, the team shows that in Huntington’s disease models — worms with pathogenic polyglutamine repeats — gtr-1 loss is also protective, but through an opposing mechanism: amyloid-beta is cleaved into small, non-toxic pieces, whereas huntingtin is sequestered into large, immobile clumps. Since small, mobile protein oligomers are the true toxic species, both degradation and sequestration can be protective. The protective pathways diverge at the genetic level: defense against amyloid-beta requires the stress-response transcription factor SKN-1, while protection from huntingtin depends on DAF-16, a key regulator of longevity in worms. This same SKN-1/DAF-16 switch was first linked to protein aggregation defense by the Cohen lab twenty years ago in *Science*, 2006, under Andrew Dillin; since then, the team has sought the signals that activate these switches context-specifically. Disrupting the wrong switch abolishes protection entirely. Neuropeptides relay signals from neurons to peripheral tissues; knocking down gtr-1 in response to amyloid-beta alters expression of 388 worm genes, while the same manipulation in Huntington’s models affects 1,213 genes — over three times as many. Of four neuropeptides essential for protection, one, nlp-59, behaves inversely: dispensable for amyloid-beta defense but required for huntingtin resistance. Thus, the nervous system diagnoses the threatening protein and broadcasts a tailored signal set. Tissues then enhance two protein-clearance systems: the proteasome, which shreds proteins, and autophagy, which packages them into vesicles for degradation. Chemically inhibiting the proteasome fully eliminates protection against huntingtin, even when gtr-1 remains suppressed. Key questions remain: how neurons coordinate proteostasis across the whole organism is only partially understood, and the mechanism by which a neuron identifies the offending protein is still unknown. The authors propose two unverified hypotheses — signaling via glial cells or the intestine — but neither was tested here. They suggest that administering a tailored combination of neuropeptides, or other signaling molecules, could delay or even prevent onset of late-onset neurodegenerative diseases in humans. Science Advances, October 9, 2024 🔗 Read original →

Male mice lose tumor-recognizing T cells faster with age; suppressing male hormones boosts immunotherapy response October 9, 2026 Nature Aging published a study on how early thymic decline — the organ that produces new T cells — and the diversion of some of these cells reduce the pool of receptors capable of recognizing tumors in lymph nodes. Temporary suppression of male sex hormones in middle-aged male mice replenished this pool and strengthened the response to immunotherapy. The antitumor T-cell response begins in the lymph node, where immune cells deliver tumor fragments. Naive CD8⁺ T cells — immune cells encountering such a fragment for the first time — must include a rare group with a receptor matching the tumor. This group proliferates, and its descendants migrate to the tumor. The fewer naive cells present, the lower the chance of this initial encounter. Researchers compared male and female mice aged 9 to 12 months, implanting B16-OVA melanoma cells tagged with a protein marker to track tumor-recognizing T cells. In males, lymph nodes were smaller, contained fewer naive CD8⁺ T cells, and tumors grew faster than in females. Depleting CD8⁺ T cells eliminated the sex difference. Immune cells of both sexes delivered tumor fragments to lymph nodes and presented them to T cells equally, so the focus shifted to the receptor pool. The depletion of this pool was explained by two processes: the thymus produces new naive T cells, but in male mice, its age-related shrinkage begins earlier. Simultaneously, some naive CD8⁺ T cells enter a “virtual memory” state without encountering their antigen. These cells have shorter lifespans and frequently leave lymph nodes, causing the original receptor repertoire to be used up more quickly. In human datasets, the authors also found smaller lymph node volumes in men and an age-related decline in the proportion of naive CD8⁺ T cells in blood. Then, middle-aged male mice received temporary suppression of male sex hormones. This increased cell numbers in the thymus and replenished lymph nodes with new naive CD8⁺ T cells. After this preparation, mice showed enhanced recognition of tumor antigens and stronger responses to anti-PD-1 antibody — a receptor that restrains T-cell activity. The effect was weaker in older males. 🔗 Read original →

On October 9, John Rom Brink published an essay proposing that AI be tasked with finding connections between already known methods Brink distinguishes two kinds of scientific tasks: one requiring new data, concepts, or theory; the other where all necessary elements already exist in papers, code, and measurements but remain disconnected. He argues the second type represents a distinct reservoir of work for AI. A researcher may know their field’s methods well yet fail to see how a technique from another discipline could answer their question. In Brink’s framing, a model reads a broad corpus, matches its parts, and suggests applying a method from one area to a problem in another. “Everything needed for the solution already existed in the knowledge corpus, but no one had connected these elements.” The impetus for this framework was OpenAI’s mathematical release on October 6. The company published results, a repository, manuscripts, and proof formalizations in Lean — a language where programs verify logical steps. Brink suspects many mathematical results from this corpus could have emerged when a model linked known techniques. Work by Claude with ecological equations and genomic data already offers a concrete example of such discovery. Matthew Schwartz, a Harvard physicist and visiting researcher at Anthropic, explained in the project description why a technically correct calculation still needs expert vetting. “In nearly all cases, Claude was technically right, but a result became genuinely interesting only after an expert helped us choose the direction.” In biology, this chain ends at lab experience. An agent may propose a link or calculation, but an experiment tests it on a living system. A Brink acquaintance working in virology and immunology calls this verification a bottleneck. The practical task for an agent begins with three decisions: which disparate materials to compare, which method to transfer, and which measurement to use to validate the result. 🔗 Read original →

Telomerase in blood-forming cells extends lifespan of immune-deficient fish without telomere lengthening In a preprint posted on Research Square on October 9, biologists reported that boosting telomerase activity in hematopoietic tissue prolonged the lives of rag1-deficient zebrafish — which lack adaptive immunity — without significantly lengthening telomeres in those cells. The rag1 mutation leads to age-related gut barrier dysfunction and microbiota dysregulation. By overexpressing tert, the catalytic subunit of telomerase, specifically in blood-forming cells, researchers observed an average lifespan increase of about eight months in mutant fish. While telomere length in hematopoietic tissue showed no statistically significant change, the intervention altered gene expression related to stress and inflammation in that tissue, reduced cell death in the intestine, decreased hepatic vacuolation, and partially restored microbiota composition toward a healthy profile. Notably, antibiotic treatment from three months of age reduced bacterial load, lowered inflammatory gene expression in gut and hematopoietic tissues, and improved survival. Conversely, transplanting microbiota from mutant fish into healthy recipients transmitted inflammatory and intestinal dysfunction markers. These findings contrast with a 2023 study where intestinal tert expression lengthened telomeres and extended lifespan in telomerase-null fish, suggesting tissue-specific mechanisms of telomerase action beyond telomere maintenance. Research Square preprint, October 9, 2024 🔗 Read original →

Danaher to Launch Autonomous AI Lab at Abcam for Antibody Discovery by Early 2027 Danaher announced on October 7, 2026, that it will launch an autonomous AI laboratory within its subsidiary Abcam to discover affinity reagents — molecules that selectively bind to a specified target, including antibodies. The company calls this the first autonomous AI lab in its portfolio, where AI will design reagent candidates, and robots and instruments will perform repetitive experiments in a closed-loop cycle: AI proposes a variant, the automated lab synthesizes and tests it, and the results feed back into the model to inform the next design. Danaher emphasizes that key scientific decisions will remain with human scientists. For instrument coordination and robotics, Danaher is partnering with Automata. Once operating at full scale, the company expects to accelerate reagent discovery up to eightfold and increase annual output up to tenfold — from tens to hundreds of reagents per year. Press release, Danaher, October 7, 2026 🔗 Read original →

Fyodor Urnov: IVF can avoid known family mutation without editing embryo DNA October 9 gene-editing researcher Fyodor Urnov challenged Origin Genomics’ argument for correcting disease-causing DNA variants in embryos in an X post. He compared it to IVF: if among the obtained embryos there is a variant without the known family mutation, it can be selected for uterine transfer. In Origin Genomics’ statement, co-founder Katie Tai explained the idea: in a formed organ the editor must be delivered to many cells, whereas in an early embryo cells are few. The company proposes studying such correction for severe monogenic diseases—diseases caused by a change in a single gene. Urnov responds that a known family mutation can often be bypassed already with IVF: oocytes are fertilized outside the body, several embryos are obtained and their cells are tested. If one embryo did not inherit the pathogenic variant, it is selected for transfer. A 2014 clinical report describes such a case for hereditary prion disease. Among eight embryos obtained via IVF, six did not carry the F198S variant; two were transferred, and the patient gave birth to healthy twins. DNA editing addresses a different starting situation: when every obtained embryo carries the family variant. In a reply in the same thread Urnov attributed possible future application to families where both parents carry two copies of ApoE4—a DNA variant linked to increased Alzheimer’s risk. He gave the timeline as “ten years and more.” The dispute concerns the family’s starting situation: selection chooses an embryo without the known mutation among those already obtained, whereas editing attempts to correct the mutation in the embryo itself. 🔗 Read original →

Glutaminase blockade improved muscle strength in mice with progeria model In a study published October 7 in Aging Cell, researchers examined aging muscle progenitor cells and found that high activity of the enzyme GLS1 was linked to urea accumulation and impaired mitochondrial function. The drug CB-839 suppressed GLS1; after one month of treatment, mice with a progeria model showed improved muscle strength, walking speed, and endurance in hanging tests. Mitochondria help cells generate energy. To induce aging in human myoblasts — cells that form muscle fibers — the authors used three methods: DNA damage, oxidative stress, and prolonged culture. In all three models, intracellular urea levels rose. To test urea’s role, the team inhibited SLC14A1, the protein that exports urea from cells. In young myoblasts, this caused urea to accumulate, while oxygen consumption and respiratory chain protein levels dropped, showing that excess urea can directly disrupt cellular respiration. The GLS1 hypothesis built on prior work by the same lab in another cell type, where glutamine breakdown was also tied to urea buildup. In the current study, aging myoblasts showed increased GLS1 activity — the enzyme that initiates glutamine breakdown. The authors demonstrated that the p38 cellular stress signaling pathway boosts GLS1 activity. CB-839 reduced GLS1 activity and urea levels, while mitochondrial respiration improved in cells. LAKI mice with an LMNA gene mutation and signs of accelerated aging received CB-839 three times weekly for one month. In their muscles, GLS1 activity and urea decreased; respiratory chain protein levels, muscle fiber cross-sectional area, and the number of Pax7-positive cells involved in muscle repair increased. Researchers then measured contraction force via electrical stimulation. Treated mice showed greater single-contraction force and force during frequent pulse trains, with faster relaxation after contraction. In movement tests, the same mice traversed a one-meter runway more quickly and hung longer on an inverted grid. Thus, the authors demonstrated both cellular changes and measurable improvements in muscle function in this mouse model of progeria. 🔗 Read original →

GSK tests Chai Discovery's protein variants and gains access for drug discovery On October 9, Chai Discovery and GSK announced a collaboration. Prior to the agreement, GSK tested protein variants proposed by Chai's models for its therapeutic targets in its own laboratory. To find a protein drug, researchers first select a therapeutic target — a molecule in the body they wish to modulate. Then they seek a binder: a protein that can attach to that target. Chai proposed such variants for GSK's targets without specialized model training on each one. The model operates experimentally: it suggests protein sequences. The lab tests these variants on real molecules and measures whether they bind to the intended target and the strength of that binding. Thus, a computational variant becomes a lab-validated result. GSK tested these variants on several targets and found binders for each one tested. Following this validation, GSK and Chai expanded their work into a collaboration. GSK will gain access to Chai's models for predicting protein folding — their structure — and for designing new variants in its drug discovery programs. 🔗 Read original →

Alveolar cells help repair bronchioles after lung injury in mice In a study published October 7 in Nature, researchers used different genetic labels to track alveolar and bronchiolar cells in mice. These labels persisted in the cells and their descendants. After chemical injury, some alveolar cells gave rise to new cells in the bronchioles, and the experiments also traced the signals guiding this transition. Alveoli are tiny lung sacs where blood picks up oxygen, while bronchioles are airways leading to them. Alveolar type 2 (AT2) cells maintain the alveoli; bronchioles are lined in part by club cells, which secrete a protective fluid. An older genetic label remained in both AT2 cells and BASC — rare stem cells at the alveolus-bronchiole border. A new labeling scheme gave these groups distinct tags, allowing researchers to track each contribution separately. Four weeks after chemical injury, 52% of the regenerated club cells originated from AT2 cells. Another 27% came from BASC, and 15% from pre-existing club cells. AT2 descendants appeared in the bronchioles as both club cells and ciliated cells, which move mucus along the airways. In this repair, AT2 cells first moved toward the bronchiole, and then some of them became club cells. Immune cells near the injured bronchiole secreted the protein SPP1 — a signal that attracted AT2 cells to the injury site. AT2 cells recognized this signal via integrin β1, a receptor protein on their surface. Surviving ciliated cells passed along the signal JAG1, which activated the Notch pathway and directed AT2 cells to become club cells. In separate experiments, blocking SPP1 or integrin β1 reduced AT2 cell movement, while interfering with Notch reduced club cell formation. In this mouse model, cells from the gas exchange zone became part of the repair of an adjacent lung region. 🔗 Read original →